Terfenadine: Difference between revisions
m Protected "Terfenadine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 20: | Line 20: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
[[Terfenadine]] is an [[antihistamine]] formerly used for the treatment of [[allergy|allergic]] conditions. It was marketed under various brand names including '''Seldane''' in the United States, '''Triludan''' in the United Kingdom, and '''Teldane''' in Australia. It was superseded by [[fexofenadine]] in the 1990s due to the risk of cardiac [[arrhythmia]] caused by [[QT interval]] prolongation. | [[Terfenadine]] is an [[antihistamine]] formerly used for the treatment of [[allergy|allergic]] conditions. It was marketed under various brand names including '''Seldane''' in the United States, '''Triludan''' in the United Kingdom, and '''Teldane''' in Australia. It was superseded by [[fexofenadine]] in the 1990s due to the risk of cardiac [[arrhythmia]] caused by [[QT interval]] prolongation. | ||
| Line 34: | Line 34: | ||
[[Category:Prodrugs]] | [[Category:Prodrugs]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:43, 20 August 2012
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 70% |
| Elimination half-life | 3.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C32H41NO2 |
| Molar mass | 471.673 g/mol |
|
WikiDoc Resources for Terfenadine |
|
Articles |
|---|
|
Most recent articles on Terfenadine Most cited articles on Terfenadine |
|
Media |
|
Powerpoint slides on Terfenadine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Terfenadine at Clinical Trials.gov Clinical Trials on Terfenadine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Terfenadine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Terfenadine Discussion groups on Terfenadine Patient Handouts on Terfenadine Directions to Hospitals Treating Terfenadine Risk calculators and risk factors for Terfenadine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Terfenadine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Terfenadine is an antihistamine formerly used for the treatment of allergic conditions. It was marketed under various brand names including Seldane in the United States, Triludan in the United Kingdom, and Teldane in Australia. It was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Terfenadine is a prodrug, generally completely metabolised to the active form fexofenadine by intestinal CYP3A4. Terfenadine itself, however, has a cardiotoxic effect and may be absorbed and reach myocytes if the patient is concurrently taking a CYP3A4 inhibitor (e.g. erythromycin, grapefruit juice).
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antihistamines
- Withdrawn drugs
- Prodrugs